Trial Profile
Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 05 Apr 2023 Status changed from recruiting to discontinued.
- 11 Jun 2019 Status changed from not yet recruiting to recruiting.
- 12 Feb 2019 Planned initiation date changed from 1 Oct 2018 to 1 Apr 2019.